CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
CUV - CLINUVEL PHARMACEUTICALS LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.02
Index: ASX300 | ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.02
Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$15.62
14 May |
0.460 OPEN $15.20 |
3.03% HIGH $15.67 |
97,417 LOW $15.08 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 100% |
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY22 Actual |
FY23 Actual |
FY24 Forecast |
FY25 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | N/A | 69.5 | xxx |
DPS (cps) | xxx | N/A | 6.3 | xxx |
EPS Growth | xxx | N/A | N/A | xxx |
DPS Growth | xxx | N/A | N/A | xxx |
PE Ratio | xxx | N/A | 21.8 | xxx |
Dividend Yield | xxx | N/A | 0.4% | xxx |
Div Pay Ratio(%) | xxx | N/A | 9.1% | xxx |
Last ex-div: 06/09 - ex-div 4c (franking 100%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 61.9 |
DPS All | xxx | xxx | xxx | xxx | xxx | 5.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 78.3 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 333.2 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 36.9 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 39.08 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 21.09 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 20.97 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 18.04 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 21.09 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 27.98 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 33.9 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 0 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 157 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 5.37 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 1.0 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 1.31 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 28 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 10 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 1 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
CUV STOCK CHART
FNArena News on CUV
1 |
Rudi’s View: Quality Reigns, And How To Identify ItMay 01 2024 - Rudi's View |
2 |
The Short Report – 21 Mar 2024Mar 21 2024 - Weekly Reports |
3 |
Weekly Ratings, Targets, Forecast Changes – 15-03-24Mar 18 2024 - Weekly Reports |
4 |
Australian Broker Call *Extra* Edition – Mar 12, 2024Mar 12 2024 - Daily Market Reports |
5 |
Australian Broker Call *Extra* Edition – Mar 06, 2024Mar 06 2024 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
Dr Boreham’s Crucible: InvionMay 13 2024 - Small Caps |
2 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
3 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
4 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
5 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
6 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
7 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
8 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
9 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
10 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |